Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon
被引:187
作者:
Jo, Sang Kyung
论文数: 0引用数: 0
h-index: 0
机构:
Univ Virginia, Dept Med, Charlottesville, VA USAUniv Virginia, Dept Med, Charlottesville, VA USA
Jo, Sang Kyung
[1
]
Rosner, Mitchell H.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Virginia, Dept Med, Charlottesville, VA USAUniv Virginia, Dept Med, Charlottesville, VA USA
Rosner, Mitchell H.
[1
]
Okusa, Mark D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Virginia, Dept Med, Charlottesville, VA USAUniv Virginia, Dept Med, Charlottesville, VA USA
Okusa, Mark D.
[1
]
机构:
[1] Univ Virginia, Dept Med, Charlottesville, VA USA
来源:
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
|
2007年
/
2卷
/
02期
关键词:
D O I:
10.2215/CJN.03280906
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.